Since HSP90i and ATRi are already used to treat various types of cancer in clinical phase I/II trials [13, 14, 63], their combinations could further increase their effectiveness and improve the prognosis of patients, especially for BRCA- and p53-deficient tumor entities. Here, TP53 is linked to neoplasm.